These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27515672)

  • 1. The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review.
    Wang Z; Sheng L; Yang Y; Yang F; Xiao X; Hua J; Guo C; Wei Y; Tang R; Miao Q; Zhang J; Li Y; Fang J; Qiu D; Krawitt EL; Bowlus CL; Gershwin ME; Wang Q; Ma X
    Clin Rev Allergy Immunol; 2017 Jun; 52(3):424-435. PubMed ID: 27515672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.
    Ichai P; Duclos-Vallée JC; Guettier C; Hamida SB; Antonini T; Delvart V; Saliba F; Azoulay D; Castaing D; Samuel D
    Liver Transpl; 2007 Jul; 13(7):996-1003. PubMed ID: 17370335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure.
    Zhu B; You SL; Wan ZH; Liu HL; Rong YH; Zang H; Xin SJ
    World J Gastroenterol; 2014 Jun; 20(23):7473-9. PubMed ID: 24966618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score.
    De Martin E; Coilly A; Chazouillères O; Roux O; Peron JM; Houssel-Debry P; Artru F; Silvain C; Ollivier-Hourmand I; Duvoux C; Heurgue A; Barge S; Ganne-Carrié N; Pageaux GP; Besch C; Bourlière M; Fontaine H; de Ledinghen V; Dumortier J; Conti F; Radenne S; Debette-Gratien M; Goria O; Durand F; Potier P; Di Martino V; Reboux N; Ichai P; Sebagh M; Mathurin P; Agostini H; Samuel D; Duclos-Vallée JC;
    J Hepatol; 2021 Jun; 74(6):1325-1334. PubMed ID: 33503489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis.
    Wang Q; Selmi C; Zhou X; Qiu D; Li Z; Miao Q; Chen X; Wang J; Krawitt EL; Gershwin ME; Han Y; Ma X
    J Autoimmun; 2013 Mar; 41():140-5. PubMed ID: 23187010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver dysfunction and fibrosis as predictors of biochemical response to autoimmune hepatitis treatment.
    Soares JC; Borgonovo A; Maggi DC; Pasinato AP; Ramos FG; Dantas-Corrêa EB; Schiavon LL; Narciso-Schiavon JL
    Minerva Gastroenterol Dietol; 2016 Jun; 62(2):138-47. PubMed ID: 27091035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
    Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
    J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of age in presentation, response to therapy and outcome of autoimmune hepatitis.
    Baven-Pronk MAMC; Biewenga M; van Silfhout JJ; van den Berg AP; van Buuren HR; Verwer BJ; van Nieuwkerk CMJ; Bouma G; van Hoek B
    Clin Transl Gastroenterol; 2018 Jul; 9(6):165. PubMed ID: 29961755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort study.
    Plagiannakos CG; Hirschfield GM; Lytvyak E; Roberts SB; Ismail M; Gulamhusein AF; Selzner N; Qumosani KM; Worobetz L; Hercun J; Vincent C; Flemming JA; Swain MG; Cheung A; Chen T; Grbic D; Peltekain K; Mason AL; Montano-Loza AJ; Hansen BE;
    J Hepatol; 2024 Aug; 81(2):227-237. PubMed ID: 38527524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Hepatology; 2007 Oct; 46(4):1138-45. PubMed ID: 17668882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome.
    Yeoman AD; Westbrook RH; Zen Y; Bernal W; Al-Chalabi T; Wendon JA; O'Grady JG; Heneghan MA
    J Hepatol; 2014 Oct; 61(4):876-82. PubMed ID: 24842305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey.
    Joshita S; Yoshizawa K; Umemura T; Ohira H; Takahashi A; Harada K; Hiep NC; Tsuneyama K; Kage M; Nakano M; Kang JH; Koike K; Zeniya M; Yasunaka T; Takaki A; Torimura T; Abe M; Yokosuka O; Tanaka A; Takikawa H;
    J Gastroenterol; 2018 Sep; 53(9):1079-1088. PubMed ID: 29476251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis.
    Yasui S; Fujiwara K; Yonemitsu Y; Oda S; Nakano M; Yokosuka O
    J Gastroenterol; 2011 Mar; 46(3):378-90. PubMed ID: 20821236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome.
    Al-Chalabi T; Underhill JA; Portmann BC; McFarlane IG; Heneghan MA
    Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1389-95; quiz 1287. PubMed ID: 18840547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis.
    Yeoman AD; Westbrook RH; Zen Y; Maninchedda P; Portmann BC; Devlin J; O'Grady JG; Harrison PM; Heneghan MA
    Hepatology; 2011 Mar; 53(3):926-34. PubMed ID: 21374663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis.
    Weber S; Benesic A; Rotter I; Gerbes AL
    Liver Int; 2019 Oct; 39(10):1906-1917. PubMed ID: 31319011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of poor response to therapy in Autoimmune Hepatitis.
    Muratori P; Lalanne C; Bianchi G; Lenzi M; Muratori L
    Dig Liver Dis; 2016 Sep; 48(9):1078-81. PubMed ID: 27378707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.
    Czaja AJ; Carpenter HA
    J Hepatol; 2004 Apr; 40(4):646-52. PubMed ID: 15030981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, biochemical and histological features related to treatment response and prognosis in autoimmune hepatitis.
    Guedes LR; Cançado GGL; Santos BC; Jacomassi LDS; Nardelli MJ; Osório FMF; Faria LC; Couto CA
    Ann Hepatol; 2024; 29(4):101497. PubMed ID: 38460715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overlap of primary biliary cirrhosis and autoimmune hepatitis: Characteristics, therapy, and long term outcomes.
    Yokokawa J; Saito H; Kanno Y; Honma F; Monoe K; Sakamoto N; Abe K; Takahashi A; Yokokawa H; Ohira H
    J Gastroenterol Hepatol; 2010 Feb; 25(2):376-82. PubMed ID: 19817953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.